Boron. Boron is found (in the form of borates) in the oceans, rocks, coal, shale and some soils. Boron accumulates in plants.

Size: px
Start display at page:

Download "Boron. Boron is found (in the form of borates) in the oceans, rocks, coal, shale and some soils. Boron accumulates in plants."

Transcription

1 Part Trace Elements Risk Assessment Boron General information Chemistry Boron is a non-metallic element, which is found abundantly in nature, though only in compounds and in combination with sodium and oxygen. Examples of compounds containing boron are borax (Na 2 B 4 O 7.10H 2 O) and boric acid (H BO ). Within this risk assessment the word boron is used as a generic term for boron compounds. For comparative purposes doses of boron compounds are expressed as boron equivalents. Natural occurrence Boron is found (in the form of borates) in the oceans, rocks, coal, shale and some soils. Boron accumulates in plants. Occurrence in foods, food supplements and medicines Boron is present in foods, particularly nuts (14 mg/kg), fresh fruits ( mg/kg) and green vegetables (2 mg/kg). Boron is present in a number of multi-vitamin and mineral food supplements at levels up to 10 mg, but not in licensed medicines in the UK. Other sources of exposure Intakes of boron from drinking water are estimated to be mg/day. Exposure from cosmetics and consumer products (where boron is used as a preservative and ph adjuster) has been estimated to be up to 0.47 mg/day. Recommended amounts COMA was unable to make specific recommendations for boron intake. The World Health Organisation (WHO) acceptable range of intake is 1-1 mg boron/day for adults. Analysis of tissue levels and boron status The preferred methods for analysis of boron in bone and plasma are inductively coupled plasma atomic emission spectroscopy and more commonly inductively coupled plasma mass spectrometry. Blood and urine measurements of boron are suitable indicators of excessive boron intake. Brief overview of non-nutritional beneficial effects It has been claimed that boron alleviates some symptoms of osteoarthritis and rheumatoid arthritis. 164

2 Expert Group on Vitamins and Minerals 200 Function Boron is an essential element in plants and is presumed to be essential in animals, since boron deprivation in both experimental animals and humans causes changes in biological function which are reversible by restoration of boron. The function of boron is unknown, but it may be involved in metabolism and utilisation of various elements (including calcium, copper, magnesium), glucose, triglycerides, reactive oxygen and oestrogen. Deficiency Boron deficiency has not been observed definitively in human populations. However, it has been suggested that boron deficiency could be a contributing factor to Kashin-Beck disease (KBD), a musculoskeletal deficiency, which may cause severe joint deformity. Kashin-Beck disease affects children in China and the former Soviet Union, and has also been linked to selenium deficiency. A crosssectional survey in China found significantly lower boron levels in the hair of children with KBD than in that of local children without KBD. Other authors have reported that short periods of restricted boron intake may affect brain function and cognitive performance in healthy humans. In animals, boron deficiency is associated with symptoms which include reduced growth rate and decreased blood steroid hormone levels. Interactions Studies in animals and in humans have demonstrated that boron interacts with the metabolism of calcium, reducing its rate of excretion and increasing serum levels, but the mechanism is uncertain. Absorption and bioavailability Boron as borate is readily, and almost completely, absorbed from the human gut. The mechanism has not been defined. Distribution and metabolism Boron, as borate, is distributed evenly, via passive diffusion, throughout body fluids. The highest levels are found in bone, which possibly represents a second kinetic compartment, as elimination kinetics for bone differ from those of soft tissue and body fluids. It has been shown that boron compounds can cross the human placenta. Boron compounds are not metabolised in biological systems. Excretion Boron is predominantly excreted in the urine as borate. 165

3 Part Trace Elements Toxicity Human data Data from accidental poisonings indicate that the acute, lethal dose of boric acid is mg for infants and 15,000-20,000 mg for adults. Clinical effects include irritability, seizures and gastrointestinal disturbances. There have also been reports of inflammation, congestion, oedema, exfoliative dermatitis, exfoliation of the mucosa, and findings of cloudy swelling and granular degeneration of renal tubular cells. Clinical symptoms of boron toxicity have been reported within the dose range 100 to 55,500 mg depending on age/body weight. Inter-individual variability appears to be high. Long-term exposure to boron in animal studies has been reported to affect male fertility. However, borax miners had a non-significant excess of births compared to the general population and a nonsignificant excess of female births compared to males in a study of 542 occupational workers in a borax mine (Whorton et al., 1994). No effects on fertility were apparent in a Turkish population exposed to boron in drinking water at levels up to 29 mg/l. Supplementation studies No adverse effects were identified in female volunteers supplemented with mg boron/day for 1 year (Meacham et al., 1994). However, 10 mg boron/day for 4 weeks increased plasma oestradiol and testosterone levels in adult male volunteers (Naghii and Samman, 1997). Plasma oestradiol was also increased in peri-menopausal women supplemented with 2.5 mg boron/day for 60 days (Nielsen and Penland, 1999). Animal data Boron compounds have moderate acute toxicity, with lethal doses in the range mg boron equivalents/kg body weight. Symptoms and signs include depression, ataxia, convulsions and weight loss. Damage to the kidneys and nerve cells were observed on histopathological examination. Long-term exposure to boron has been associated with reduced body weights and decreased pancreas, spleen and kidney weights. Boron has been shown to cause specific adverse effects in the male reproductive tract in all species, including shrunken scrota, inhibited spermiation and degeneration of seminiferous tubules with loss or absence of germ cells. However, mating behaviour in the animals was unaffected. Developmental toxicity has been reported following administration of boron to pregnant rats and rabbits. Carcinogenicity and genotoxicity There is no evidence of carcinogenicity from oral exposure to boron compounds in rats and mice. Boron compounds are not mutagenic in bacterial or in vitro mammalian cell mutation assays. 166

4 Expert Group on Vitamins and Minerals 200 Mechanism of toxicity Boric acid may affect DNA synthesis in germ cells and energy metabolism in Sertoli cells, possibly affecting the production of early germ cells. The mechanism by which boron inhibits spermiation is uncertain. Dose-response characterisation In humans, the lethal dose of boric acid is mg for infants and mg for adults. Clinical symptoms are apparent within the dose range 100 to mg depending on age/body weight. Vulnerable groups Pregnant women are a potential vulnerable group, as indicated by results of animal reproductive studies. Genetic variations No genetic variations have been identified. Studies of particular importance in the risk assessment (For full review see or the enclosed CD). Weir and Fisher, 1972 Ten Sprague Dawley rats of each sex per group were fed diets containing borax or boric acid for 90 days, at levels providing 2.6, 8.8, 26., 87.5 or 26 mg boron/kg bw/day. At the highest dose 100% mortality occurred. At 87.5 mg boron kg/bw/day, liver, kidney, spleen, testes, ovaries and body weights were decreased. Histological changes were observed in the adrenals at 87.5 mg boron/kg bw/day. Testicular atrophy occurred at 26. and 87.5 mg/kg bw/day. Detailed results were provided for the 87.5 mg/kg bw/day dose group only. Thirty five Sprague Dawley rats/sex/group were fed diets containing borax or boric acid for 2 years at levels providing 5.9, 17.5 and 58.5 mg boron/kg bw/day. Growth rate was decreased, absolute and relative testes weights were decreased and relative brain and thyroid weights were increased at the top dose. Histological changes in the testes were observed in the top dose group. No other effects were apparent. Limited results were reported. Five beagle dogs/group were fed diets containing borax or boric acid for 90 days, at levels providing 0.44, 4.4 or 44 mg boron/kg bw/day. In the group given the highest dose, one death occurred, histological changes in the adrenals and thyroid, and severe testicular atrophy were observed, and whereas relative weights of thyroid and testes were reduced, those of liver and brain were increased. 167

5 Part Trace Elements Four beagle dogs of each sex per group were fed diets containing borax or boric acid for 2 years, at levels providing 1.45, 2.9 and 8.75 mg boron/kg bw/day. No treatment related effects were found. Limited results were reported in the paper. In a second study, additional groups were given mg boron/kg bw/day for 8 weeks. Histological changes in the testes were apparent, but (based on one animal) were reversible when treatment was stopped. Eight male and sixteen female Sprague Dawley rats/group were fed diets containing borax or boric acid for 14 weeks prior to mating and for subsequent generations. The doses were provided 5.9, 17.5 and 58.5 mg boron/kg bw/day. No adverse effects were reported in the low and mid dose groups. The high dose animals were, however, sterile when mated with control animals. Decreased ovulation and lack of viable sperm were apparent. Limited results were provided in the paper. Heindel et al., 1992 Feed containing boric acid at levels providing 1.6, 28.5, 57.7 mg boron/kg bw/day was given to pregnant Sprague Dawley rats throughout gestation (an additional group received 94.2 mg boron/kg bw/day on days 6-25 only). Decreased body weight gain was found in the dams in the 57.7 and 94.2 mg boron/kg bw/day dose groups and increased liver and kidney weights at 28.5 mg boron/kg bw/day and above. Average foetal body weight/litter was reduced in the offspring of the dams in all dose groups. Pre-natal mortality was increased in the 94.2 mg boron/kg bw/day group only. The incidence of malformed foetuses was increased at 28.5 mg boron/kg bw/day and above. The malformations and anatomical variations included enlarged lateral ventricles of the brain and shortening of rib XIII. The authors noted that developmental toxicity was occurring at lower doses than maternal toxicity. Feed containing boric acid was given to groups of 10 pregnant Swiss mice throughout gestation. The average doses provided by the feed were 4., 79.0 or 175 mg boron/kg bw. Minor renal lesions were found in the dams at all doses, and decreased body weights and increased relative kidney weights at the highest dose.in the mice given the highest dose, the number of resorptions and malformed foetuses was increased, and foetal body weights were reduced in offspring. The malformations and anatomical variations included an increased incidence of short rib XIII and a decreased incidence of rudimentary or full ribs at lumbar 1, and were present at all dose levels. The authors argued that since the renal lesions were minor and occurred in 2/10 mice in the low dose group compared with 8/10 and 10/10 in the higher dose groups, that this dose level approached a NOAEL for maternal toxicity. Thus, as with the rat, developmental toxicity was occurring at lower doses than maternal toxicity. Price et al., 1996 This study is a follow up to the Heindel et al. rat study and was designed to establish a NOAEL. Groups of 60 pregnant female Sprague Dawley rats were given feed containing boric acid throughout gestation. The average doses provided in the feed were 0,., 6.4, 9.6, 1.1 or 25.2 mg boron/kg bw/day. The only maternal effect observed was increased relative kidney weight at the 25.2 mg boron/kg bw/day level. There was no effect on pre-natal mortality. Foetal body weights were reduced in the offspring of the 1.1 and 25.2 mg boron/kg bw/day groups but had recovered by birth. The incidence of short rib XIII was increased in foetal rats at 1.1 and 25.2 mg boron/kg bw/day, but at 25.2 mg boron/kg bw/day only in pups of 21 days of age. The incidence of wavy rib was also increased in foetal rats at 1.1 and 25.2 mg boron/kg bw/day but was reversed in pups of 21 days of age. A slight decrease in the incidence of extra lumbar ribs was observed at 25.2 mg boron/kg bw/day in the day 20 foetuses. The authors concluded that the NOAEL was 9.6 mg boron/kg bw/day for foetal effects and 1.1mg boron/kg bw/day for 168

6 Expert Group on Vitamins and Minerals 200 maternal toxicity. Developmental toxicity was noted to be occurring at lower doses than maternal toxicity. This is a well-reported study and is consistent with findings of Heindel et al. Exposure assessment Total exposure/intake: Food Mean: 1.5 mg/day (1994 TDS). 97.5th percentile: 2.6 mg/day Water mg/day (IPCS 1998) Supplements up to 10 mg/day (Annex 4) Cosmetics and consumer products up to 0.47 mg/day Maximum estimated intake: = 14 mg/day Vegetarians have been identified as a potential high intake group. Risk assessment In animals, the main toxic effect associated with boron involves the reproductive system. Boron caused specific adverse effects in the male reproductive tract in rats, mice and dogs, including shrunken scrota, inhibited spermiation and degeneration of seminiferous tubules with loss or absence of germ cells. Boron also caused a reduction in ovulation in female rats and renal lesions in female mice. Boron also causes developmental toxicity, with foetal malformations occurring in mice and rats at levels lower than those associated with maternal toxicity. The human data are scarce, although a study in two Turkish populations (Sayli et al., 1998a) demonstrated that higher levels of boron in well water appeared not to affect reproduction. Similarly, Whorton et al. (1994) examined the standardised birth ratio (SBR) in US borate workers. No effects on fertility were apparent (the SBR was increased compared to the general population), a small but insignificant excess of female births was found in both studies. Neither study investigated more sensitive markers of reproductive toxicity or the effects of boron on neonatal body weight, this being the limiting toxicity in the animal studies. The human epidemiology data are negative but could be compatible with the available animal data since they involved lower exposure levels than used in the animal studies. However, limited conclusions can be drawn from these studies due to the relative insensitivity of the end-points measured. There was no effect on fertility, but more subtle effects on sperm quality (which could be significant in sub-fertile men) or on other aspects of reproductive health could not be ruled out. The supplementation trial by Naghii and Samman, found that 10 mg boron/day for 4 weeks significantly increased plasma oestradiol 169

7 Part Trace Elements levels in male volunteers. The clinical significance of the increase is uncertain. The study is of interest, but limited due to the small numbers involved and the lack of follow up. Other studies have not demonstrated this effect but lower doses of boron were used. Boron has also been reported to enhance the effects of oestrogen in post-menopausal women taking oestrogen therapy. Further work on the effects of boron on the endocrine system is therefore desirable. ESTABLISHMENT OF SAFE UPPER LEVEL Key Study: Price et al. (1996). NOAEL: 9.6 mg boron/kg bw/day. Uncertainty 10 for inter-species variation x 6 for inter-individual variation Factor: in humans = 60 Safe Upper Level for daily consumption over a lifetime: 9.6/60 = 0.16 mg boron/kg bw/day (equivalent to 9.6 mg boron/day for a 60 kg adult). The key adverse effect associated with boron is reproductive toxicity. However, the human data are limited regarding reproductive toxicity and so the SUL is based on animal studies. Reproductive toxicity is apparent in laboratory animals, with characteristic effects being produced in the testes. A clear doseresponse relationship has been demonstrated. The NOAELs for reproductive effects are 4.4 mg boron/kg bw/day in dogs and 9.6 mg boron/kg bw/day in rodents. Similar effects are observed in different animal species. A Safe Upper Level can be derived from animal data with the appropriate use of uncertainty factors. Although the Weir and Fisher study resulted in the lower NOAEL of 4.4 mg/kg bw/day, the number of animals in this study was low and the differences between the dose levels tested were large, so that the lowest dose at which adverse effects were observed was ten times this level. Considering the totality of the data, the highest intake without significant adverse effects (the NOAEL) is 9.6 mg/kg bw/day, based on the study of Price et al. (1996) and so this has been used to establish an SUL. The usual uncertainty factor of 10 for differences between animals and humans was used to allow for the known differences in renal clearance of boron between animals and humans, and to allow for the possibility that human tissues may be inherently more sensitive than rat tissues. The factor of 10 for inter-individual variability in humans was revised to a chemical-specific adjustment factor of 6 as proposed by Dourson et al. (1998). This comprises a factor of 1.8 to allow for glomerular filtration in some women being 2 standard deviations below the average, and a factor of.1 to allow for possible, but undefined, inter-subject variability in tissue sensitivity. Pregnant women are a potential vulnerable group given the effects of boron on foetal weights. However, the critical animal studies cover this endpoint and there appears to be no need for an additional uncertainty factor. This results in a safe upper level for total intake of 9.6 mg boron/day for a 60 kg adult. This is higher than the present maximum UK intake from food, water and consumer products (estimated to be up to.7 mg boron/day), suggesting a margin of 6 mg/day for supplemental intake. 170

8 Expert Group on Vitamins and Minerals 200 References Dourson, M., Maier, A., Meek, B., Renwick, A., Ohanian, E., Poirier, K. (1998) Re-evaluation of toxicokinetics for data-derived uncertainty factors. Biological Trace Element Research 66, Heindel, J.J., Price, C.J., Field, E.A., Marr, M.C., Myers, C.B., Morrissey, R.E., Schwetz, B.A. (1992) Developmental toxicity of boric acid in mice and rats. Fundamental And Applied Toxicology 18, IPCS (1998) Environmental Health Criteria 204: Boron. World Health Organization, Geneva, Switzerland. Meacham, S.L., Taper, L.J., Volpe, S.L. (1994) Effects of boron supplementation on bone mineral density and dietary, blood, and urinary calcium, phosphorus, magnesium, and boron in female athletes. Environmental Health Perspectives 102, Naghii, M.R., Samman, S. (1997) The effect of boron supplementation on its urinary excretion and selected cardiovascular risk factors in healthy male subjects. Biological Trace Element Research 56, Nielsen F.H., Penland J.G. (1999). Boron supplementation of peri-menopausal women affects boron metabolism and indices associated with macromineral metabolism, hormonal status and immune function. Journal of Trace Elements in Experimental Medicine 12, Price, C.J., Strong, P.L., Marr, M,C,, Myers. C,B,, Murray, F.J. (1996a) Developmental toxicity NOAEL and postnatal recovery in rats fed boric acid during gestation. Fundamental and Applied Toxicology 2, Sayli, B.S., Tuccar, E., Elhan, A.H. (1998). An assessment of fertility in boron-exposed Turkish subpopulations. Reproductive Toxicology 12, Weir, R.J., Fisher, F.S. (1972) Toxicologic studies on borax and boric acid. Toxicology and Applied Pharmacology 2, Whorton, M.D., Haas, J.L., Trent, L., Wong, O. (1994) Reproductive effects of sodium borates on male employees: birth rate assessment. Occupational and Environmental Medicine 51,

Justification of classification of boron compounds in European Union

Justification of classification of boron compounds in European Union Justification of classification of boron compounds in European Union Boguslaw Baranski, Beata Peczkowska Bureau for Chemical Substances 30/34 Dowborczyków Street 90-019 Lódz, Poland Boric acid and borates

More information

Questions and answers on boric acid and borates used as excipients in medicinal products for human use

Questions and answers on boric acid and borates used as excipients in medicinal products for human use 9 October 2017 EMA/CHMP/619104/2013 Committee for Human Medicinal Products (CHMP) Questions and answers on boric acid and borates used as excipients in medicinal products for human use Draft agreed by

More information

Draft agreed by Excipients Drafting group 16 June Adopted by CHMP for release for consultation 23 July 2015

Draft agreed by Excipients Drafting group 16 June Adopted by CHMP for release for consultation 23 July 2015 1 2 3 23 July 2015 EMA/CHMP/619104/2013 Committee for Human Medicinal Products (CHMP) 4 5 6 7 8 Questions and answers on boric acid in the context of the revision of the guideline on Excipients in the

More information

Dithianon DITHIANON (180)

Dithianon DITHIANON (180) Dithianon 201 5.11 DITHIANON (180) TOXICOLOGY Dithianon (C 14 H 4 N 2 O 2 S 2 ) is the International Organization for Standardization (ISO) approved name for 5,10-dihydro-5,10-dioxonaphtho[2,3-b]-1,4-dithiine-2,3-dicarbonitrile

More information

Risk Assessment Report on Tris (nonylphenyl)phosphite (TNPP)

Risk Assessment Report on Tris (nonylphenyl)phosphite (TNPP) EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON HEALTH AND ENVIRONMENTAL RISKS SCHER

More information

5.17 PENTHIOPYRAD (253)

5.17 PENTHIOPYRAD (253) Penthiopyrad 189 5.17 PENTHIOPYRAD (253) TOXICOLOGY Penthiopyrad is the International Organization for Standardization (ISO) approved name for N-[2- (1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide

More information

5.36 THIOPHANATE-METHYL (077)

5.36 THIOPHANATE-METHYL (077) 391 5.36 THIOPHANATE-METHYL (077) TOXICOLOGY is the International Organization for Standardization (ISO) approved common name for dimethyl 4,4 -(o-phenylene)bis(3-thioallophanate) (International Union

More information

5.15 HEXYTHIAZOX (176)

5.15 HEXYTHIAZOX (176) Hexythiazox 225 5.15 HEXYTHIAZOX (176) TOXICOLOGY Hexythiazox is the ISO approved name for (trans-5-(4-chlorophenyl)-n-cyclohexyl-4-methyl-2-oxo- 3-thiazolidine-carboxamide (CAS No. 78587-05-0). Hexythiazox

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/527/98-FINAL January 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS AZAMETHIPHOS SUMMARY REPORT

More information

5.24 TRIAZOLE FUNGICIDE METABOLITES

5.24 TRIAZOLE FUNGICIDE METABOLITES Triazole metabolites 355 5.24 TRIAZOLE FUNGICIDE METABOLITES TOXICOLOGY 1,2,4-Triazole, triazole alanine, triazole acetic acid, triazole pyruvic acid and triazole lactic acid are the common metabolites

More information

European Public MRL assessment report (EPMAR)

European Public MRL assessment report (EPMAR) 8 September 2015 EMA/CVMP/632934/2014 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Propyl 4-hydroxybenzoate and its sodium salt (all food producing

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/114/96-FINAL June 1996 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS EPRINOMECTIN SUMMARY REPORT

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology Unit EMEA/MRL/050/95-FINAL February 1996 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS AMINOSIDINE

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/488/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS DIETHYLENE GLYCOL MONOETHYL

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology Unit EMEA/MRL/718/99-FINAL January 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS PAROMOMYCIN

More information

DANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR

DANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR NCTR Research Plan for BPA: Integrating pharmacokinetics in rodent and primate species, rat toxicology studies, human biomonitoring, and PBPK modeling to assess potential human risks from dietary intake

More information

5.3 AZINPHOS METHYL (002)

5.3 AZINPHOS METHYL (002) 5.3 AZINPHOS METHYL (002) TOXICOLOGY Azinphos-methyl is the ISO approved common name for S-3,4-dihydro-4-oxo-1,2,3-benzotriazin-3- ylmethyl O,O-dimethyl phosphorodithioate (IUPAC) or O,O-dimethyl S-[(4-oxo-1,2,3-benzotriazin-

More information

Cycloxydim CYCLOXYDIM (179)

Cycloxydim CYCLOXYDIM (179) Cycloxydim 125 5.9 CYCLOXYDIM (179) TOXICOLOGY Cycloxydim is the ISO approved name for (5RS)-2-[(EZ)-1-(ethoxyimino)butyl]-3-hydroxy-5-[(3RS)- thian-3-yl]cyclohex-2-en-1-one (IUPAC). The CAS chemical name

More information

Boric Acid and its Salts (Boron)

Boric Acid and its Salts (Boron) Proposed Re-evaluation Decision PRVD2012-03 Boric Acid and its Salts (Boron) (publié aussi en français) 16 October 2012 This document is published by the Health Canada Pest Management Regulatory Agency.

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/888/03-FINAL June 2004 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS OXFENDAZOLE (Extrapolation to all ruminants) SUMMARY REPORT (4)

More information

5.2 ATRAZINE TOXICOLOGY

5.2 ATRAZINE TOXICOLOGY . 5.2 ATRAZINE TOXICOLOGY Atrazine, 6-chloro-N 2 -ethyl-n 4 -isopropyl-1,3,5-triazine-2,4-diamine (International Union of Pure and Applied Chemistry, IUPAC) (CAS No. 1912-24-9), is a selective systemic

More information

Dichlorvos DICHLORVOS (025)

Dichlorvos DICHLORVOS (025) Dichlorvos 63 5.7 DICHLORVOS (025) TOXICOLOGY Dichlorvos is the International Organization for Standardization (ISO) approved common name for 2,2-dichlorovinyl dimethyl phosphate (International Union of

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/615/99-FINAL Rev.1 1 May 2008 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS 1-METHYL-2-PYRROLIDONE SUMMARY REPORT (2) 1. 1-Methyl-2-pyrrolidone

More information

3-MCPD and glycidol and their esters

3-MCPD and glycidol and their esters Toxicological Risk Assessment of 3-monochloropropane-1,2-diol (3-MCPD) Esters and Glycidol Esters: Is there a Need for Concern? Ivonne M.C.M. Rietjens Division of Toxicology Wageningen University ivonne.rietjens@wur.nl

More information

DANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR

DANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR Research support by Interagency Agreement between NTP/NIEHS and NCTR/FDA The opinions presented are not necessarily those of the U.S. FDA or NTP NCTR/FDA Research on BPA: Integrating pharmacokinetics in

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/77290/05-FINAL March 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE FLUAZURON SUMMARY REPORT 1. Fluazuron is an insect

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/267/97-FINAL October 1997 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS FLUBENDAZOLE SUMMARY REPORT

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/526/98-FINAL January 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS APRAMYCIN SUMMARY REPORT

More information

Captan (Pesticides) Summary. Risk assessment report. Food Safety Commission of Japan. Conclusion in Brief

Captan (Pesticides) Summary. Risk assessment report. Food Safety Commission of Japan. Conclusion in Brief 2017 Food Safety Commission, Cabinet Office, Government of Japan doi: 10.14252/foodsafetyfscj.2017003s Food Safety 2017; Vol. 5, No. 2, 61 66 Risk assessment report Captan (Pesticides) Summary Food Safety

More information

OPINION ON. Boron compounds

OPINION ON. Boron compounds Revision of 28 September 2010 Scientific Committee on Consumer Safety SCCS OPINION ON Boron compounds The SCCS adopted this opinion at its 7 th plenary meeting of 22 June 2010 About the Scientific Committees

More information

GSC CODEX MESSAGE CCFA48/2016/25

GSC CODEX MESSAGE CCFA48/2016/25 FORM FOR THE SUBMISSION OF SUBSTANCES TO BE EVALUATED BY JECFA In completing this form, only brief information is required. The form may be retyped if more space is needed under any one heading provided

More information

- draft scientific opinion -

- draft scientific opinion - The Re-evaluation of faspartame - draft scientific opinion - Dr. Alicja Mortensen Chair of EFSA s ANS Panel Follow-up meeting on the web-based public consultation on aspartame 9 April 2013, Bruxelles Draft

More information

SCIENTIFIC COMMITTEE ON TOXICITY, ECOTOXICITY AND THE ENVIRONMENT (CSTEE) Opinion on the results of the Risk Assessment of:

SCIENTIFIC COMMITTEE ON TOXICITY, ECOTOXICITY AND THE ENVIRONMENT (CSTEE) Opinion on the results of the Risk Assessment of: EUROPEAN COMMISSION DIRECTORATE-GENERAL HEALTH AND CONSUMER PROTECTION Directorate C - Scientific Opinions Unit C2 Management of Scientific Committees; scientific co-operation and networks Scientific Committee

More information

Information on vitamins. Good for eyes, sight, skin and growth. Excess is harmful to pregnant women who should avoid vitamin A rich foods.

Information on vitamins. Good for eyes, sight, skin and growth. Excess is harmful to pregnant women who should avoid vitamin A rich foods. Information on vitamins. Vitamin A. Good for eyes, sight, skin and growth. Excess is harmful to pregnant women who should avoid vitamin A rich foods. Cod liver oil. Butter. Double cream. Cheese. Vitamin

More information

Boron and Medical Health. By Jorge D. Flechas MD, MPH, Hendersonville, N. C.

Boron and Medical Health. By Jorge D. Flechas MD, MPH, Hendersonville, N. C. Boron and Medical Health By Jorge D. Flechas MD, MPH, Hendersonville, N. C. Jorge D. Flechas M.D., M.P.H., H(M.D.), 13/11/2016 General Information About Boron Boron is a metalloid element with similar

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/546/99-FINAL January 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS EMAMECTIN SUMMARY REPORT

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/016/95-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS COLISTIN SUMMARY REPORT (1) 1. Colistin

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/452/98-FINAL June 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NITROXINIL SUMMARY REPORT 1.

More information

Folpet (Pesticides) Summary. Risk assessment report. Food Safety Commission of Japan. Conclusion in Brief

Folpet (Pesticides) Summary. Risk assessment report. Food Safety Commission of Japan. Conclusion in Brief 2017 Food Safety Commission, Cabinet Office, Government of Japan doi: 10.14252/foodsafetyfscj.2017002s Food Safety 2017; Vol. 5, No. 2, 67 71 Risk assessment report Folpet (Pesticides) Summary Food Safety

More information

Status of Activities on BPA

Status of Activities on BPA Committed since 2002 to ensuring that Europe s food is safe Status of Activities on BPA at International Level Anna F. Castoldi FIP Unit Meeting with National Experts Parma, 29-30 October 2012 International

More information

This document is submitted by the lead registrant, BASF SE on behalf of the Methanol REACH Consortium

This document is submitted by the lead registrant, BASF SE on behalf of the Methanol REACH Consortium This document is submitted by the lead registrant, BASF SE on behalf of the Methanol REACH Consortium Date: 10/12/2013 RE: ECHA Consultation period 29/10/2013 to 13/12/2013 on Harmonised Classification

More information

ILMC Tool Box Series 4.6. General Population and Community Issues. Health Issues for Lead Workers and the General Population. 1.

ILMC Tool Box Series 4.6. General Population and Community Issues. Health Issues for Lead Workers and the General Population. 1. For non-occupationally exposed populations, blood lead levels are generally reflective of lead exposure from multiple environmental media. Once again, relationships between exposure level and subsequent

More information

APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELS FOR BBP

APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELS FOR BBP Helsinki, 2 September 20 RAC/26/20/07 Rev. (Agreed at RAC-26) APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELS FOR BBP Background At the 22 nd meeting of the Committee for Risk Assessment (RAC)

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/339/98-FINAL May 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS VALNEMULIN SUMMARY REPORT 1.

More information

Initial Assessment. Coriander Seed Oil

Initial Assessment. Coriander Seed Oil Initial Assessment Coriander Seed Oil Name of Applicant: Nestec Ltd. Contact person(s): Nigel Baldwin, Intertek Cantox Novel Food Classification: 2.1. Introduction An application for the authorisation

More information

International Safety Assessment of Sweeteners

International Safety Assessment of Sweeteners ILSI SEA Region Seminar on Uses and Safety of Sweeteners (May 2013) http://www.ilsi.org/sea_region/pages/vieweventdetails.aspx?webid=4d540914-eeb6-40e4-89eb- 0B73BA3D76C1&ListId=478BE3CB-581B-4BA2-A280-8E00CCB26F9C&ItemID=73

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/580/99-FINAL April 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS BARIUM SELENATE SUMMARY REPORT

More information

COCAM 3, October 2012 SIDS INITIAL ASSESSMENT PROFILE

COCAM 3, October 2012 SIDS INITIAL ASSESSMENT PROFILE SIDS INITIAL ASSESSMENT PROFILE Category Name Aryl Substituted Dialkyl Peroxides CAS No(s). 80-43-3 25155-25-3 Chemical Name(s) 1,1'-(Dioxydipropane-2,2-diyl)dibenzene (DCUP) [1,3(or 1,4)-Phenylenebis(1-methylethylidene)]bis[tert-butyl]

More information

What are the challenges in addressing adjustments for data uncertainty?

What are the challenges in addressing adjustments for data uncertainty? What are the challenges in addressing adjustments for data uncertainty? Hildegard Przyrembel, Berlin Federal Institute for Risk Assessment (BfR), Berlin (retired) Scientific Panel for Dietetic Foods, Nutrition

More information

DIETARY RISK ASSESSMENT

DIETARY RISK ASSESSMENT lambda Cyhalothrin 91 The maximum dietary burden for poultry is 1.3 ppm. No residues above the LOQ of the analytical method used were observed in the feeding study for laying hens at the lowest dose level

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/503/98-FINAL November 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS BROMHEXINE SUMMARY REPORT

More information

Opinion On Arsenic, Barium, Fluoride, Boron And Manganese In Natural Mineral Waters (Expressed On 13 December 1996)

Opinion On Arsenic, Barium, Fluoride, Boron And Manganese In Natural Mineral Waters (Expressed On 13 December 1996) Opinion On Arsenic, Barium, Fluoride, Boron And Manganese In Natural Mineral Waters (Expressed On 13 December 1996) Terms of reference To advise on the acceptability from the public health point of view

More information

Principles of nutrition Lesson B

Principles of nutrition Lesson B Principles of nutrition Lesson B Sam - ID 38359016 Unit: Applying the principles of nutrition to a physical activity programme Learning outcomes & assessment criteria Learning outcome: The learner will:

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/815/02-FINAL January 2002 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS COLISTIN SUMMARY REPORT

More information

1 Risk Assessment Vitamin C

1 Risk Assessment Vitamin C Part Water Soluble Vitamins Risk Assessment Vitamin C General information Chemistry Vitamin C is a six-carbon compound structurally related to glucose, consisting of two inter-convertible compounds: L-ascorbic

More information

Safety Assessment of Citicoline

Safety Assessment of Citicoline Safety Assessment of Citicoline Name of Applicant: Kyowa Hakko Europe GmbH Contact person(s): Nigel Baldwin, Intertek Cantox Novel Food Classification: 1.1. Introduction An application for the authorisation

More information

DICHLOROACETONITRILE. 1. Exposure Data

DICHLOROACETONITRILE. 1. Exposure Data DICHLOROACETONITRILE Data were last evaluated in IARC (1991). 1. Exposure Data 1.1 Chemical and physical data 1.1.1 Nomenclature Chem. Abstr. Serv. Reg. No.: 3018-12-0 Chem. Abstr. Name: Dichloroacetonitrile

More information

Mineral, Health and Vitality Formula

Mineral, Health and Vitality Formula Mineral, Health and Vitality Formula Maintaining optimal mineral levels, enjoying peak health and increasing your body s vitality are now more accessible than ever. OptimALL Nutrition balance is an allnatural,

More information

Boron and Inflammation

Boron and Inflammation By Jorge D. Flechas MD, MPH, Hendersonville, N. C. Financial Disclosure: Shareholder in Treetop Essentials. General Information About Boron Boron is a metalloid element with similar properties to silicon.

More information

DR. SHAMSUL AZAHARI ZAINAL BADARI DEPARTMENT OF RESOURCES MANAGEMENT AND CONSUMER STUDIES FACULTY OF HUMAN ECOLOGY UPM

DR. SHAMSUL AZAHARI ZAINAL BADARI DEPARTMENT OF RESOURCES MANAGEMENT AND CONSUMER STUDIES FACULTY OF HUMAN ECOLOGY UPM DR. SHAMSUL AZAHARI ZAINAL BADARI DEPARTMENT OF RESOURCES MANAGEMENT AND CONSUMER STUDIES FACULTY OF HUMAN ECOLOGY UPM Mineral nutrients are inorganic elements found in food which the body cannot synthesis.

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/904/04-FINAL June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE ALTRENOGEST SUMMARY REPORT (3) 1. Altrenogest (or allyltrenbolone)

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/175/96-FINAL December 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ALTRENOGEST SUMMARY REPORT

More information

Opinion on Voluntary Risk Assessment Report on lead and lead compounds. Human Health Part

Opinion on Voluntary Risk Assessment Report on lead and lead compounds. Human Health Part Scientific Committee on Health and Environmental Risks SCHER Opinion on Voluntary Risk Assessment Report on lead and lead compounds Human Health Part CAS No: 7439-92-1, 1317-36-8, 1314-41-6, 69011-06-9,

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/140/96-FINAL October 1996 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS THIOMERSAL AND TIMERFONATE

More information

Zinc: Issues and Update. Craig Boreiko, Ph.D. Ottawa May 2008

Zinc: Issues and Update. Craig Boreiko, Ph.D. Ottawa May 2008 Zinc: Issues and Update Craig Boreiko, Ph.D. Ottawa May 2008 Topics Basics of zinc deficiency and essentiality Nutrition vs Toxicology Effects of elevated zinc intake Comparison of risk assessments Concluding

More information

TOXICITY DATA (continued): KETOCONAZOLE (continued): TDLo (Oral-Rat) 1760 mg/kg: female 1-21 day(s) after conception: Reproductive: Maternal Effects: other effects; Fertility: post-implantation mortality

More information

DIBROMOACETONITRILE. 1. Exposure Data

DIBROMOACETONITRILE. 1. Exposure Data DIBROMOACETONITRILE Data were last evaluated in IARC (1991). 1. Exposure Data 1.1 Chemical and physical data 1.1.1 Nomenclature Chem. Abstr. Serv. Reg. No.: 3252-43-5 Chem. Abstr. Name: Dibromoacetonitrile

More information

FSANZ Response to Studies Cited as Evidence that BPA may cause Adverse Effects in Humans

FSANZ Response to Studies Cited as Evidence that BPA may cause Adverse Effects in Humans Annex 1 FSANZ Response to Studies Cited as Evidence that BPA may cause Adverse Effects in Humans STUDY KEY FINDINGS/CLAIMS FSANZ RESPONSE Relative binding affinity-serum modified access (RBA-SMA) assay

More information

Read-across illustrative example

Read-across illustrative example Part 2 Example 1 Analogue approach: similarity based on breakdown products Annankatu 18, P.O. Box 400, FI-00121 Helsinki, Finland Tel. +58 9 686180 Fax +58 9 68618210 echa.europa.eu 2 Example 1 DISCLAIMER

More information

CHLOROTHALONIL METABOLITE R (addendum)

CHLOROTHALONIL METABOLITE R (addendum) CHLOROTHALONIL METABOLITE R611965 (addendum) First draft prepared by G. Wolterink 1 and V. Dellarco 2 1 Centre for Substances and Integrated Risk Assessment, National Institute for Public Health and the

More information

4. Contaminants. 4.1 Aluminium (from all sources, including food additives)

4. Contaminants. 4.1 Aluminium (from all sources, including food additives) WHO Technical Report Series 940 EVALUATION OF CERTAIN FOOD ADDITIVES AND CONTAMINANTS Sixty-seventh report of the Joint FAO/WHO Expert Committee on Food Additives Food and Agriculture Organization of the

More information

SIAM 19, October 2004 SIDS INITIAL ASSESSMENT PROFILE SUMMARY CONCLUSIONS OF THE SIAR

SIAM 19, October 2004 SIDS INITIAL ASSESSMENT PROFILE SUMMARY CONCLUSIONS OF THE SIAR SIDS INITIAL ASSESSMENT PROFILE CAS No. 67-56-1 Chemical Name Methanol Structural Formula CH 3 OH SUMMARY CONCLUSIONS OF THE SIAR Human Health Toxicokinetics, Metabolism, and Distribution: Methanol is

More information

The Menopause What is the menopause? Symptoms of the menopause Hormone Replacement Therapy (HRT)

The Menopause What is the menopause? Symptoms of the menopause Hormone Replacement Therapy (HRT) The Menopause Over 20% of the female population is post-menopausal and it is estimated that by 2025 there will be 13.6 million women over 50 years of age in the UK. It is vital then that women know what

More information

Part 2. Chemical and physical aspects

Part 2. Chemical and physical aspects Part 2. Chemical and physical aspects 12. Chemical and physical aspects: introduction 12.1 Background information used The assessment of the toxicity of drinking-water contaminants has been made on the

More information

The EFSA scientific opinion on lead in food

The EFSA scientific opinion on lead in food The EFSA scientific opinion on lead in food Dr Diane Benford Chemical Risk Assessment Unit Food Standards Agency Vice-Chair of the EFSA Panel on Contaminants in the Food Chain (CONTAM) Lead Ammunition

More information

Potassium Dichromate Impact on Male Reproductive Integrity Biomarker in Rat. Two Generation Study

Potassium Dichromate Impact on Male Reproductive Integrity Biomarker in Rat. Two Generation Study Potassium Dichromate Impact on Male Reproductive Integrity Biomarker in Rat. Two Generation Study Jelena Rankov, Alexandra Trif, Diana Brezovan, Florin Muselin Faculty of Veterinary Medicine 300645, Timisoara,

More information

BENZETHONIUM CHLORIDE

BENZETHONIUM CHLORIDE OPINION OF THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS INTENDED FOR CONSUMERS CONCERNING BENZETHONIUM CHLORIDE COLIPA n P 70 adopted by the SCCNFP during the 26 th plenary meeting

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/300/97-FINAL November 1997 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS AZAPERONE SUMMARY REPORT

More information

(Z)-1-Chloro-2,3,3,3-tetrafluoropropene (2017)

(Z)-1-Chloro-2,3,3,3-tetrafluoropropene (2017) WORKPLACE ENVIRONMENTAL EXPOSURE LEVEL (Z)-1-Chloro-2,3,3,3-tetrafluoropropene (2017) I. IDENTIFICATION Chemical Name: (Z)-1-Chloro-2,3,3,3-tetrafluoropropene Synonyms: HCFO-1224yd(Z) CAS Number: 111512-60-8

More information

Section 5.3: Preclinical safety data

Section 5.3: Preclinical safety data Section 5.3: Preclinical safety data SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group

More information

SCCP. Extended Opinion on. the Safety Evaluation of Parabens

SCCP. Extended Opinion on. the Safety Evaluation of Parabens EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON CONSUMER PRODUCTS SCCP Extended Opinion

More information

6 Essential Minerals for Women's Health. By Dr. Isaac Eliaz

6 Essential Minerals for Women's Health. By Dr. Isaac Eliaz 6 Essential Minerals for Women's Health By Dr. Isaac Eliaz Minerals are essential micronutrients that are required in small amounts for the body to function properly. Untreated mineral deficiencies can

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/875/03-FINAL February 2004 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MORANTEL SUMMARY REPORT

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/694/99-FINAL May 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS CHLORMADINONE SUMMARY REPORT

More information

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT

More information

DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)

DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/36147/2005-FINAL June 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE MORANTEL (Extension to all ruminants) SUMMARY REPORT

More information

APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELs FOR 1-BROMOPROPANE (1-BP)

APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELs FOR 1-BROMOPROPANE (1-BP) 1 (10) Helsinki, 09 September 2016 RAC/38/2016/09 rev 1 Final APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELs FOR 1-BROMOPROPANE (1-BP) Background At the 22 nd meeting of the Committee for

More information

Guidelines of the Scientific Committee on Food for the development of tolerable upper intake levels for vitamins and minerals

Guidelines of the Scientific Committee on Food for the development of tolerable upper intake levels for vitamins and minerals EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Scientific Opinions C3 - Management of scientific committees II; scientific co-operation and networks Scientific Committee

More information

Health Effects of GenX: What do we know and what do we need to know to protect public health?

Health Effects of GenX: What do we know and what do we need to know to protect public health? Health Effects of GenX: What do we know and what do we need to know to protect public health? Jamie DeWitt, PhD, DABT Department of Pharmacology & Toxicology Brody School of Medicine East Carolina University

More information

Mineral Nutrients. NOW Guide to Mineral Nutrients

Mineral Nutrients. NOW Guide to Mineral Nutrients Mineral Nutrients NOW Guide to Mineral Nutrients The Health Benefits of Mineral Nutrients Mineral nutrients (also called dietary elements and dietary minerals) are inorganic substances that are essential

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/606/99-FINAL June 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS CYROMAZINE SUMMARY REPORT (1)

More information

FENPYROXIMATE (addendum) First draft prepared by T.C. Marrs Food Standards Agency, London, England. Explanation

FENPYROXIMATE (addendum) First draft prepared by T.C. Marrs Food Standards Agency, London, England. Explanation 35 FENPYROXIMATE (addendum) First draft prepared by T.C. Marrs Food Standards Agency, London, England Explanation... 35 Evaluation for an acute reference dose... 35 Toxicological studies... 35 Short-term

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/MRL/451/98-FINAL June 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS BACITRACIN SUMMARY REPORT (1)

More information

Risk Assessment. Zinc. General information. Chemistry. Natural occurrence. Occurrence in food, food supplements and medicines

Risk Assessment. Zinc. General information. Chemistry. Natural occurrence. Occurrence in food, food supplements and medicines Expert Group on Vitamins and Minerals 200 Risk Assessment Zinc General information Chemistry Zinc is an abundant group IIB post-transition metallic element. It occurs in nature as the sulphide (ZnS), in

More information

The terms used in these Directives are consistent with those defined by the Committee.

The terms used in these Directives are consistent with those defined by the Committee. Opinion of the Scientific Committee for Food on: A maximum residue limit (MRL) of 0.01 mg/kg for pesticides in foods intended for infants and young children (expressed on the 19th September 1997) Terms

More information

Sudbury Human Health Risk Assessment Briefing

Sudbury Human Health Risk Assessment Briefing Sudbury Human Health Risk Assessment Briefing September 22, 2008 Prepared by Environmental Defence September 22, 2008 The following report was commissioned by Mine-Mill Local 598CAW and Local 6500 Steelworkers

More information

Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods

Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods Guidance on Novel Foods From Animal Toxicity Studies to Safe Levels of Intake in Humans Dr. Josef Schlatter Member of the Scientific Committee and EFSA s WG on Novel Foods Info-session 06 March 2017 Parma

More information

TRIS (NONYLPHENYL) PHOSPHITE SUMMARY RISK ASSESSMENT REPORT

TRIS (NONYLPHENYL) PHOSPHITE SUMMARY RISK ASSESSMENT REPORT TRIS (NONYLPHENYL) PHOSPHITE CAS-No.: 26523-78-4 EINECS-No.: 247-759-6 SUMMARY RISK ASSESSMENT REPORT Final report, 2007 France Rapporteur for the risk assessment of tris(nonylphenyl) phosphite is the

More information

ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY

More information